FDA warns Genzyme on French plant

Clean up your act, Genzyme--or so says the FDA, which found "significant violations" of manufacturing rules at a French plant that produces the company's Thymoglobulin drug for kidney transplants.

Inspectors found higher-than-allowable levels of bacteria in some of the drug's components and concluded that the company didn't investigate those failures rigorously enough. Nor did the company thoroughly investigate the death of two animals during drug-safety tests. The company says it's heeding the FDA warning and already working to address the agency's concerns.

- read the FDA warning letter
- check out the report from the Boston Herald

Related Articles:
Boston officials herald big Genzyme expansion. Report
Manufacturing woes plague launch of Myozyme. Report
Genzyme reports successful late-stage stem cell study. Report
Genzyme shifts focus after hylastan fails trial. Report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.